Introduction: Adverse drug reactions (ADRs) are harmful, unintended drug responses occurring at standard therapeutic doses. They pose a major global health and economic burden, especially among older adults. Prevention is feasible through systematic interventions—particularly pharmacist-led—and by strengthening pharmacovigilance systems at national and international levels. Addressing ADRs effectively improves patient safety, reduces healthcare costs, and optimizes therapeutic outcomes. Material and Methods: ADRs that took place in admitted patients were taken into consideration for analysis. Information about ADR was collected in the ADR reporting form. Result: From January to July 2025, 32 ADRs were reported. The age of patients who underwent ADR ranged between 16 and 83 years. All the ADRs were divided into three categories based upon severity, and the highest number of ADR (85%) belong to the mild category, whereas 9% and 6% of ADR belong to the moderate and severe categories. Conclusion: ADR reporting is a critical component of pharmacovigilance, ensuring safe and effective use of medicines in real-world practice. Timely reporting by healthcare professionals, patients, and institutions helps identify risks that may not have been detected during clinical trials.
Roy et al. (Wed,) studied this question.